Study of ARCT-810 for people with OTC deficiency
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests an experimental medicine called ARCT-810 for people with Ornithine Transcarbamylase (OTC) deficiency, a condition that affects the liver's ability to remove ammonia from the body. The study aims to see if ARCT-810 can help lower ammonia levels safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older.
- You have been diagnosed with OTC deficiency by a doctor.
- You have had symptoms of high ammonia in the past, but your condition has been stable for at least one month.
- You are on a stable treatment plan (diet, supplements, or medicines) for at least 28 days.
- You have not received gene therapy or stem cell therapy for OTC in the past 2 years.
- You do not have a history of organ transplant, cancer (except treated skin cancer), or certain heart or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests an AAV gene therapy meant to reduce ammonia levels in children with ornithine transcarbamylase (OTC) deficiency. It’s designed to slow or stop ammonia-related harm, while also carefully monitoring safety for years.
This trial tests a new medicine called LNP.UCD.ABE that aims to fix a specific genetic change causing a severe urea cycle disorder. It uses a technique called base editing to correct the gene mutation, which may help your body break down ammonia better.
This trial studies blood and other measurable signs (biomarkers) that may reflect brain injury after certain inherited metabolic conditions. Results may help doctors better detect and understand brain effects from these illnesses, especially episodes that affect the brain.
This study tests an investigational drug called KRRO-121. It is first tested in healthy volunteers to check safety, and then in patients with urea cycle disorder (a condition where the body can't remove ammonia properly) to see if it helps.
This trial tests a device for measuring ammonia levels at home in people with rare metabolic conditions that cause high ammonia. It aims to make monitoring easier and more convenient for patients.
This early (first-in-human) study tests whether OATD-02 is safe and tolerable, and whether it shows any anti-cancer activity. It is for adults with certain advanced or metastatic cancers that have already been treated with the standard options.
Hear when a new Ornithine Transcarbamylase Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.